CYP19A1 and neoplasm: Because aromatase contributes to multiple facets of tumor progression and clinical trials demonstrate higher benefit in patients treated with aromatase inhibitors compared to tamoxifen [60], recommendations have been made to incorporate an AI to reduce the risk of breast cancer recurrence [61].